Sirous Sadeghian Chaleshtori

Dr. Sirous Sadeghian Chaleshtori


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2018 in Critical Care
Verified
Journal Article
Open access
PDF file
MDMohammad Reza Mokhber Dezfouli
Mohammad Reza Mokhber Dezfouli
MFMassoumeh Jabbari Fakhr
Massoumeh Jabbari Fakhr
SCSirous Sadeghian Chaleshtori
Sirous Sadeghian Chaleshtori
MDMohammad Mehdi Dehghan
Mohammad Mehdi Dehghan
AVAlireza Vajhi
Alireza Vajhi
RMRoshanak Mokhtari
Roshanak Mokhtari
Lung diseases such as acute respiratory distress syndrome (ARDS) have a high incidence worldwide. The current drug therapies for ARDS have supportive effects, making them inefficient. New methods such as stromal cell therapy are needed for this problem. This research was performed with ten New Zealand rabbits in two groups. Bone marrow aspiration was performed on the treated group, and mesenchymal stem cells were isolated and cultured. The experimental model of ARDS was induced using LPS from Escherichia coli strain O55:B5. Then, 1010 bone marrow mesenchymal stem cells (BM-MSCs) were autologously transplanted intrapulmonary in the treatment group, and 1–2 ml of PBS in the control group. The clinical signs, computed tomographic (CT) scans, echocardiography, blood gas analysis, complete blood count, and cytokine levels were measured before and at 3, 6, 12, 24, 48, 72, and 168 h after BM-MSC transplant. Finally, the rabbits were killed, and histopathological examination was performed. The results showed that BM-MSCs decreased the severity of clinical symptoms, the number of white blood cells and heterophils in the blood, the total cell count, and number of heterophils and macrophages in bronchoalveolar lavage, and balanced the values of arterial blood gases (increase in partial pressure of oxygen and O2 saturation and decrease in the partial pressure of carbon dioxide). They also downregulated the tumor necrosis factor (TNF)-α and interleukin (IL)-6 concentrations and increased the IL-10 concentrations at different times compared with time 0 and in the control group, significantly. In the CT scan, a significant decrease in the Hounsfield units and total lung volume was found by echocardiography, and in comparing the two groups, a significant difference in the parameters was noticed. The histopathology demonstrated that the BM-MSCs were able to reduce the infiltration of inflammatory cells and pulmonary hemorrhage and edema. This study indicated that BM-MSCs play a significant role in the repair of lung injury.

11 May 2020 in Respiratory Research
Verified
Journal Article
Open access
PDF file
SCSirous Sadeghian Chaleshtori
Sirous Sadeghian Chaleshtori
MDMohammad Reza Mokhber Dezfouli
Mohammad Reza Mokhber Dezfouli
MFMassoumeh Jabbari Fakhr
Massoumeh Jabbari Fakhr
The pulmonary diseases are one of the most important causes of death in the world. The successful therapies in the field of lung diseases are very limited and the medical treatments available are ineffective in many of the lung diseases. Many studies have evaluated the new therapies in the acute pulmonary diseases, and the transplantation of mesenchymal stem/stromal cells (MSCs), which is a branch of cell therapy, has a special place among the new medical techniques. The MSCs are present throughout the body and are thought to play a role in tissue regeneration and inflammation control. In the event of injury, the local MSCs traverse the shortest possible distance from the tissue or blood vessels to reach the affected site. But, there are few undifferentiated cells in the tissues. The exogenous MSCs are used to immunity modify or regenerative treatments in preclinical models of acute pulmonary diseases. Several studies have shown the positive effects of MSCs replacement in the acute lung disorders. The effection mechanism of the MSCs include the differentiation ability and the secretion of paracrine agents such as the anti-inflammatory mediators. Many studies suggest that this treatment method is safe and is probably to be widely used in future clinical trials. This review will describe the therapeutic effects of the MSCs in the experimental models of the acute pulmonary diseases for use as a method of treatment in clinical trials in future.

28 June 2023
Verified
Journal Article
Open access
ANAfshin Noori
Afshin Noori
MDMohammad Reza Mokhber Dezfouli
Mohammad Reza Mokhber Dezfouli
SRSarah Rajabi
Sarah Rajabi
FGFatemeh Ganji
Fatemeh Ganji
ZGZahra Ghezelayagh
Zahra Ghezelayagh
YTYaser Tahamtani
Yaser Tahamtani
Objective: Efficient production of functional and mature alveolar epithelial is a major challenge for developing any cell replacement therapy for lung degenerative diseases. The extracellular matrix (ECM) pro-vides a dynamic environment and mediates cellular responses during development and maintenance of tissue functions. The decellularized ECM (dECM) which retains its native-like structure and bio-chemical composition can provide the induction of embryonic stem cell (ESC) differentiation toward the tissue-specific lineages during in vitro culture. Therefore, the aim of this study was to evaluate the effect of sheep lung dECM-derived scaffold on differentiation and further maturation of ESC-derived lung progenitor cells. Materials and Methods: This study was an experimental study. In the first step, a sheep lung was decellularized to achieve dECM scaffolds and hydrogels. Afterwards, the obtained dECM scaffold was evaluated for collagen and glycosaminoglycan contents, DNA quantification, and its ultrastructure. Next, the three experimental groups: i. Sheep lung dECM-derived scaffold, ii. Sheep lung dECM-derived hydrogel, and iii. Fibronectin-coated plates were compared in their abilities to induce further differentiation of human embryonic stem cells (hESCs)-derived definitive endoderm (DE) into lung progenitor cells. The comparison was evaluated by immuno-staining and real-time polymerase chain Results: We found that the dECM-derived scaffold preserved its composition and native porous structures while lacking nuclei and intact cells. All experimental groups displayed lung progenitor cell differen-tiation as revealed by the RNA and protein expression of NKX2.1, P63 and CK5. DE cells differenti-ated on dECM-derived scaffold and dECMderived hydrogel showed significant upregulation of SOX9 gene expression, a marker of the distal airway epithelium. DE cells differentiated on the dECM-derived scaffold compared to the two other groups, showed enhanced expression of SFTPC (type 2 alveolar epithelial [AT2] cell marker), FOXJ1 (ciliated cell marker), and MUC5A (secretory cell marker) genes. Conclusion: Overall, our results suggest that dECM-derived scaffold improves the differentiation of DE cells towards lung alveolar progenitor cells in comparison with dECM-derived hydrogel and fibronectin-coated plates.

1 December 2020 in Life Sciences
Verified
Journal Article
Closed access
SCSirous Sadeghian Chaleshtori
Sirous Sadeghian Chaleshtori
MDMohammad Reza Mokhber Dezfouli
Mohammad Reza Mokhber Dezfouli
JAJavad Abbasi
Javad Abbasi
MDMohammad Mehdi Dehghan
Mohammad Mehdi Dehghan
MFMassoumeh Jabbari Fakhr
Massoumeh Jabbari Fakhr
MMMohammad Mehdi Mirabad
Mohammad Mehdi Mirabad

11 June 2025 in Health Science Reports
Verified
Journal Article
Open access
SCSirous Sadeghian Chaleshtori
Sirous Sadeghian Chaleshtori
ZPZanyar Pirkani
Zanyar Pirkani
MFMassoumeh Jabbari Fakhr
Massoumeh Jabbari Fakhr
MMMona Mokhber
Mona Mokhber
Background and Aims: Pulmonary disorders significantly impact worldwide healthcare, highlighting the necessity for enhanced diagnostic and treatment approaches. This narrative review seeks to investigate the potential of extracellular vesicles (EVs) as an innovative therapeutic strategy for diverse pulmonary disorders. Methods: This review synthesizes existing data about the function of extracellular vesicles (EVs) in pulmonary health and pathology, emphasizing their modes of action, including the transfer of proteins, nucleic acids, and lipids for intercellular communication. It also examines the implications of EVs in targeted medication delivery, immunomodulation, and tissue regeneration. Results: EVs, including microvesicles and exosomes, have demonstrated promise in treating respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, pulmonary fibrosis, and acute respiratory distress syndrome (ARDS). Additionally, EVs may serve as valuable biomarkers for early disease detection, prognosis, and monitoring. However, challenges remain regarding the standardization of EV isolation methods and characterization protocols to ensure safety and clinical applicability. Conclusion: In summary, extracellular vesicles hold potential for transforming the management of pulmonary diseases by providing insights into pathophysiology, enabling early diagnosis, and facilitating personalized treatment approaches. Further exploration of EV‐based therapies is necessary to fully realize their potential in improving outcomes for lung disorders.

1 March 2024 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
HTHamid Tavanaeimanesh
Hamid Tavanaeimanesh
ZAZahra Alinia
Zahra Alinia
SCSirous Sadeghian Chaleshtori
Sirous Sadeghian Chaleshtori
HMHamidreza Moosavian
Hamidreza Moosavian
ZMZeinab Mohebi
Zeinab Mohebi
Mojtaba DaneshiMojtaba Daneshi
Mojtaba Daneshi
Background: During transportation many horses develop post-transportation infection, which can be life-threatening and end their sport career. Preventing mucus accumulation and inflammation during transportation is vital, emphasizing the need for effective strategies to enhance overall horse health welfare. Objectives: Assess the impact of N-acetylcysteine (NAC) on mucus accumulation and inflammation in horses subjected to 18 hours of head confinement. Animals: Six healthy crossbred horses, 5.3 ± 2.1 years of age and weighing 387 ± 30 kg. Methods: Prospective placebo-controlled cross-over design study. The horses' heads were restrained in their stalls for a period of 18 hours. They were studied under 4 conditions: Not confined (NC): before head confinement, placebo (P), and confined head (CH): 18 hours of head confinement without treatment, and N-Acetylcysteine (NAC): 18 hours of head confinement treated with NAC before confinement (15 mg/kg/day NAC PO for 3 days). Bronchoalveolar lavage (BAL) was performed in each condition. Mucus accumulation along the trachea was evaluated by endoscopy. Results: Endoscopic scores were significantly different between CH and other conditions, whereas no significant differences were found among NC, P, and NAC. The BAL cell count (34 291 ± 2624 cells/μL), neutrophil and lymphocyte count (18 601 ± 3193 cells/μL and 3337.4 ± 593 cells/μL, respectively) in CH were significantly higher compared to NAC. Neutrophil percentage was significantly higher in CH (53.8 ± 8%) compared to horses that received NAC (20.08 ± 8%). Conversely, in comparison to NAC (66.33 ± 9%), the percentage of macrophages was significantly lower in CH (35.7 ± 10%). Conclusions: N-acetylcysteine was found to significantly decrease mucus accumulation and inflammatory cell counts in horses with head confinement.